Form 4: Evoke Pharma Director Cam L. Garner Acquires Stock Options

Director Cam L. Garner reports acquisition of stock options in Evoke Pharma, Inc.

Summary

• Cam L. Garner, a director of Evoke Pharma Inc, filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on May 21, 2025.
• Garner acquired 1,291 stock options with an exercise price of $3.453.
• These options vest one year from the grant date, contingent on continued service.
• Following the transaction, Garner directly owns 11,520 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The director's confidence is a slight positive, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the transactions of company directors and officers, which can be indicative of their sentiment towards the company's prospects.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Evoke Pharma, Form 4, Stock Options, Director, Garner, Beneficial Ownership, Securities, Acquisition